MedTrace Logo

Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer

NCT01967862 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2020-09-17

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well fluorine F 18 sodium fluoride positron emission tomography (PET)/computed tomography (CT) and whole body and axial magnetic resonance imaging (MRI) work in finding metastases in patients with recurrent prostate cancer. New imaging techniques, such as fluorine F 18 sodium fluoride PET/CT and whole body and axial MRI, may be more effective than standard CT and bone scan in finding metastatic prostate cancer.

Conditions

  • Recurrent Prostate Cancer

Interventions

PROCEDURE

computed tomography

Undergo CT

PROCEDURE

bone scan

Undergo bone scan

PROCEDURE

3-Tesla magnetic resonance imaging

Undergo axial MRI

PROCEDURE

diffusion-weighted magnetic resonance imaging

Undergo WB MRI

RADIATION

fluorine F 18 sodium fluoride

Undergo fluorine F 18 sodium fluoride PET/CT

PROCEDURE

computed tomography

Undergo fluorine F 18 sodium fluoride PET/CT

PROCEDURE

positron emission tomography

Undergo fluorine F 18 sodium fluoride PET/CT

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Cy Stein, MD, PhD · City of Hope Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2018-09-17
Completion
2018-09-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01967862 on ClinicalTrials.gov